The aim of this study was two-fold; the first aim was to use pathway analysis to provide further evidence that KMT5A regulates oncogenic pathways and is a valid therapeutic target in prostate cancer and the second was to identify individual genes that are regulated by KMT5A in a model of castration-resistant prostate cancer as potential biomarkers for KMT5A activity. This evidence concerns the gene KMT5A and prostate carcinoma.